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Background: Asthma is a heterogeneous disease composed of various phenotypes. Periostin, a molecule
inducible with interleukin (IL)-4 or IL-13 in bronchial epithelial cells, is a biomarker of “TH2-high”
asthma. The objective of this study is to examine whether the serum periostin concentrations are
correlated with the severity, speciﬁc phenotype(s), or comorbidity of asthma.
Methods: Serum concentrations of periostin were measured in 190 Japanese asthmatic patients and 11
healthy controls. The protocol was registered under UMIN 000002980 in the clinical trial registry.
Results: The serum concentrations of periostin were signiﬁcantly higher (P ¼ 0.014) in asthmatics [70.0
(54.0e93.5) ng/ml] than in healthy subjects [57.0 (39.0e63.0) ng/ml], though we found no correlation
between serum periostin concentrations and treatment steps required to control asthma. To characterize
“high-periostin” phenotype(s), the patients with asthmawere divided among tertiles based on the serum
concentrations of periostin. The high-periostin group was older at onset of asthma (P ¼ 0.04), had a
higher prevalence of aspirin intolerance (P ¼ 0.04) or concomitant nasal disorders (P ¼ 0.03e0.001),
higher peripheral eosinophil counts (P < 0.001), and lower pulmonary function (P ¼ 0.02e0.07). The
serum concentrations of periostin were particularly high in asthmatic patients complicated by chronic
rhinosinusitis with nasal polyps and olfactory dysfunction. In contrast, neither atopic status, control
status of asthma, nor quality of life were related with the “high-periostin” phenotype.
Conclusion: Elevated periostin concentrations in serum were correlated with a speciﬁc phenotype of
eosinophilic asthma, late-onset and often complicated by obstructive pulmonary dysfunction and nasal
disorders.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.dicine, Department of Medi-
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rgology. Production and hosting by ElsIntroduction
Asthma is an inﬂammatory disease of the airways character-
ized by bronchial hyperresponsiveness and reversible airﬂow
limitation, affecting about 300 million people in the world.1 Whileevier B.V. All rights reserved.
M. Matsusaka et al. / Allergology International 64 (2015) 175e180176airway inﬂammation and respiratory symptoms can be controlled
with inhaled corticosteroids in most instances, they remain re-
fractory to the highest tolerable doses of inhaled corticosteroids,
long-acting bronchodilators, and leukotriene receptor antagonists
in patients with severe asthma.2 The frequent disease exacerba-
tions suffered by these patients, and multiple emergency depart-
ment visits and hospitalisations represent a heavy social and
economic burden.3 Furthermore, because the heterogeneous
characteristics of severe asthma preclude its control by a single
therapeutic agent, relevant phenotyping and individualized
treatment are essential.4
Interleukin (IL)-13, a TH2 cytokine, plays an important role in
the development and persistence of eosinophilic inﬂammation and
hyperresponsiveness in the asthmatic airways.5 Patients with
“TH2-high” asthma have been identiﬁed by transcriptome analysis,
whose bronchial epithelial cells express excessive amounts of IL-
13-inducible genes, such as Clca1 and Postn.6 These patients present
with increased eosinophilic inﬂammation and airway hyper-
responsiveness, thickened basement membranes, and greater
responsiveness to corticosteroids.7 On the other hand, periostin,
the product of IL-13-inducible Postn, is an extracellular matrix
protein of the fasciclin family,8 and can be measured in serum.
Serum periostin concentrations are correlated with a sustained
eosinophilic inﬂammation of the airways9 and rapid decline of
pulmonary function10 despite treatment with inhaled corticoste-
roids. Another study has suggested that the concentrations of
serum periostin can be used to predict the responsiveness to
treatment with antieIL-13 antibody.11 Therefore, periostin might
be a useful biomarker as a companion diagnostic for severe
asthma.12 However, clinical characteristics or phenotype of asth-
matics with elevated serum periostin levels are not well studied.
This study examined whether, in asthmatic Japanese, the serum
concentrations of periostin are correlated with the disease severity,
speciﬁc phenotype or comorbidity.
Methods
Patient populations
Between April 1, 2010 and December 31, 2012, we enrolled
Japanese patients 20 years of age, who presented with difﬁcult-to
treat asthma at Keio University Hospital and afﬁliated hospitals.
Asthma was diagnosed on the basis of the Japanese Society of
Allergology guideline.13 Asthma requiring step 4 or 5 treatment
actions, deﬁned in the updated version of the 2006 statement by
the Global Initiative for Asthma (GINA) to achieve its optimum
control was deﬁned as severe asthma.14 Healthy subjects with no
history of allergic diseases and patients with mild to moderate
asthma controlled with step 1 to 3 treatment actions of GINA,
served as controls. Patients with uncontrolled malignant tumours
or widespread lung disease that prominently impaired lung func-
tion were excluded from enrolment. The protocol (no 2009-9-5)
initially approved by the Institutional Review Board of Keio Uni-
versity School of Medicine, was subsequently approved by the
Review Board of each participating institution, and implemented in
compliance with the Declaration of Helsinki. All participants
granted their written informed consent.
Collection of clinical information
The study participants reported their clinical information at the
time of enrolment by means of a self-completed questionnaire.
Poor adherence to the treatment was deﬁned as < 5 day-use of
inhaled corticosteroids per week. Olfactory dysfunction was
deﬁned by the presence of hyposmia/anosmia. The control status ofasthma and the disease-speciﬁc quality of life were ascertained,
using the Japanese versions of the asthma control test15 and the
Juniper's asthma quality of life questionnaire,16,17 respectively.
Laboratory data and information pertaining to medications and
disease exacerbations were collected from medical records.
Serum concentrations of periostin and cytokines
The serum periostin concentrations were measured by enzyme-
linked immunosorbent assay, as previously reported.18 The serum
concentrations of IL-4, IL-5, and IL-13 were measured, using the
Bio-Plex® Suspension Array System (Bio-Rad Laboratories, Hercu-
les, CA, USA). Total and allergen-speciﬁc serum immunoglobulin
(Ig)E concentrations for house-dust mites, cat dander, fungi, and
insects were measured using a ﬂuorescence-enzyme immunoassay
(Mitsubishi Chemical Medience Corporation, Tokyo, Japan). Atopic
asthma was deﬁned as one or more allergen-speciﬁc IgE concen-
trations >0.70 UA/mL.
Pulmonary function tests
Pulmonary function during stable asthmawasmeasured using a
CHESTAC-9800 spirometer (Chest, Tokyo, Japan), which met the
criteria of the American Thoracic Society. The predicted value of
vital capacity (VC) and forced expiratory volume in 1 s (FEV1) for a
Japanese population was calculated using the formula proposed by
the Japanese Respiratory Society. The fraction of exhaled nitric
oxide was measured with a Sievers nitric oxide analyser (GE
Healthcare Japan, Tokyo, Japan) in some participating institutions.
High-resolution computed tomography
Airway wall thickness was measured by high-resolution
computed tomography scans, using an Aquilion™ (TOSHIBA Med-
ical Systems Corporation, Tochigi, Japan) or LightSpeed® volume
scanner (GE Healthcare). The wall area and % wall area of the apical
bronchus of the right upper lobe (RB1) were measured using the
AZE VirtualPlace Lexus64® software (AZE, Tokyo, Japan).
Statistical analysis
The data are expressed as means ± SD, median and interquartile
range, or percentages. Categorical data were analysed with the chi-
square test. ManneWhitney test or KruskaleWallis test, as appro-
priate. Spearman's rank correlation coefﬁcient was determined
between serum levels of periostin, TH2 cytokines, and blood
eosinophil counts. A regression analysis was performed to examine
the correlations between pulmonary functions and age- and sex-
adjusted or unadjusted, log-transformed serum periostin concen-
tration, duration of asthma and smoking history. A statistically
signiﬁcant difference was deﬁned as a two-tailed P value <0.05. All
statistical analyses were performed with the SPSS statistical soft-
ware package for Windows, version 20.0 (IBM Corporation,
Armonk, NY, USA).
Results
Characteristics of the study groups
This study enrolled 11 healthy subjects (mean age 39.5 ± 12.1
years, 73% men) and 190 asthmatic patients (mean age 60.2 ± 14.5
years, 44% men), including 22 in the GINA steps 1 and 2, 20 in step
3, 83 in step 4 and 65 patients in step 5. In 58 patients in step 4
(70%) and 58 patients in step 5 (89%), the status corresponded to
the deﬁnition of severe asthma by international ERS/ATS
Fig. 1. Relationship between serum periostin concentrations and severity of asthma.
The serum periostin concentrations in 11 healthy subjects 190 patients with asthma
are shown. The patients with asthma were divided between GINA treatment steps 1e3
and step 4 & 5. Bars indicate median values.
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Demographic and clinical observations
Men 38 46 0.39
Age, y 60.6 ± 14.3 60.1 ± 14.7 0.82
Age at onset of asthma, y 36.1 ± 20.1 32.6 ± 22.8 0.32
Body mass index, kg/m2 22.5 ± 3.2 24.2 ± 4.7 0.07
History of smoking 26.8 17.4 0.19
Aspirin intolerance 12.5 20.7 0.36
Atopic dermatitis 22.0 25.4 0.84
Allergic rhinitis 61.0 69.1 0.35
Chronic rhinosinusitis with nasal polyps 43.9 39.7 0.72
Olfactory dysfunction 36.6 28.3 0.34
Poor adherence to the treatment 15.4 5.1 0.04
Daily dose of inhaled corticosteroids, mgy 273 ± 195 744 ± 292 <0.001
Patients treated with daily oral
corticosteroids
0 37.8 <0.001
Patients treated with omalizumab 0 12.8 0.009
Laboratory measurements
Eosinophils/ml of blood 421 ± 667 465 ± 537 0.71







Atopic type 53.7 59.5 0.59
Pulmonary function (n ¼ 173)
VC, % predicted 98 ± 13 92 ± 19 0.03
FEV1, % predicted 91 ± 15 80 ± 23 <0.001
FEV1/FVC, % 69 ± 10 64 ± 14 0.01
Fractional exhaled nitric oxide, ppb (n ¼ 80) 29 ± 32 49 ± 51 0.03
Asthma severity and quality of life scores
Asthma Control Test 22.5 ± 3.2 18.9 ± 5.0 <0.001
Asthma Quality of Life Questionnaire 5.5 ± 1.0 4.7 ± 1.2 <0.001
Values are proportions of patients in each study groups or means ± SD if not
otherwise speciﬁed.
IgE, immunoglobulin E; VC, vital capacity; FEV1, Forced expiratory volume in 1 s;
FVC, forced vital capacity.
y Dose of inhaled corticosteroids are shown as ﬂuticasone propionate equivalent.
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included in the GINA treatment steps 1 to 3 with those of 148 pa-
tients included in steps 4 and 5. The serum concentration of total
IgE and fractional exhaled nitric oxide in the latter group were
signiﬁcantly higher, while VC, FEV1, and the asthma control test and
asthma quality of life questionnaire scores were signiﬁcantly lower.
The rate of patients with poor adherence to the treatment was
lower in severe asthma group, and there were no differences be-
tween the 2 groups in sex distributions, age, body mass index,
peripheral blood eosinophil counts, atopic status, and prevalence of
comorbidity, including aspirin intolerance, atopic dermatitis,
allergic rhinitis and chronic rhinosinusitis with nasal polyps.
Relationship between serum periostin concentrations and severity of
asthma
The median serum periostin concentrations in the 190 asth-
matic patients was 70.0 (54.0e93.5) ng/ml, versus 57.0 (39.0e63.0)
ng/ml in the 11 healthy subjects (P ¼ 0.014). There were no sig-
niﬁcant differences, however, in the serum periostin concentra-
tions measured among patients in GINA step 1-3 [66.5 (51.0e87.0)
ng/mL], step 4; 70.0 (57.0e97.0) ng/mL, and step 5; 72.0
(54.0e103.0) ng/mL (Fig. 1). Periostin concentrations 90 ng/mL,
observed in 33% of the step 4& 5 group, was found in only in 14% of
the step 1-3 group (P ¼ 0.02 compared to step 4 & 5 group) and
none of the healthy controls (P ¼ 0.02 compared to step 4 & 5
group), suggesting that a speciﬁc asthmatic phenotype(s) charac-
terized by elevated serum periostin concentrations (“periostin-
high” asthma) is more prevalent among patients requiring themost
intensive treatment.High serum periostin concentrations indicate a speciﬁc asthmatic
phenotype
To characterize the “periostin-high” phenotype of asthma, we
divided the 190 asthmatic patients among tertiles according to the
serum periostin concentrations (Table 2). The average age and age
at onset of asthma were signiﬁcantly older in the high-than in the
low-periostin group, and the prevalence of late-onset asthma (age
at onset  40 y) in high-periostin group (59.3%) was 1.7 times as
high as that in low-periostin group (34.5%, P¼ 0.009). Furthermore,
allergic rhinitis, olfactory dysfunction and aspirin-intolerance were
more prevalent, and abnormalities of pulmonary function tests and
peripheral eosinophil counts were signiﬁcantly greater in the high-
than the low-periostin group (Table 2). Finally, the serum concen-
trations of TH2 cytokines, IL-4 and IL-13, were higher in the high-
periostin group, though the difference was of borderline statisti-
cal signiﬁcance (Table 2). There was aweak to moderate correlation
between serum periostin levels and peripheral blood eosinophilia
(r ¼ 0.38, p < 0.0001) and weak correlation with TH2 cytokine
levels in serum (r ¼ 0.18-0.21, p ¼ 0.01-0.03, Supplementary Fig. 1).
When the analysis was limited to the 148 patients included in the
GINA step 4 and 5 group, the highest-periostin groupwas also older
at the time of onset of asthma, was leaner, had a higher prevalence
of nasal diseases, lower pulmonary functions, and higher serum
TH2 cytokine concentrations and peripheral eosinophil counts
(Supplementary Table 1).
Because high periostin concentrations were correlated with
nasal disorders, such as allergic rhinitis, chronic rhinosinusitis with
nasal polyps, and olfactory dysfunction (Supplementary Fig. 2),
then we examined which component(s) of the disorders deter-
mined this relationship. Fig. 2 shows that the patients who suffered
from both chronic rhinosinusitis with nasal polyps and olfactory
dysfunction had the highest serum periostin concentrations
(P ¼ 0.001 compared with the patients without nasal disorder).
FEV1 and FEV1/forced vital capacity (FVC) were lower among pa-
tients with high serum periostin concentrations (Table 2). We,
therefore, performed single and multivariate analyses to examine
whether serum periostin was correlated with obstructive pulmo-
nary dysfunction, and found that log-transformed serum periostin
concentrations were weakly correlated with FEV1/FVC (P ¼ 0.03;
Table 3), but not with %predicted FEV1 (P ¼ 0.27). By multiple
variable analysis, serum periostin concentration was marginally
correlated with FEV1/FVC independently of asthma duration or
smoking history (Table 3).
Table 2














Demographic and clinical observations
Men 44.4 39.1 49.2 0.72
Age, y 56.1 ± 15.0 60.6 ± 14.3 64.1 ± 13.4 0.002
Age at onset of asthma, y 29.4 ± 23.4 33.8 ± 24.0 36.9 ± 18.4 0.04
Early-onset asthma (age at onset < 16 y) 37.9 32.2 18.5 0.02
Late-onset asthma (age at onset  40 y) 34.5 47.5 59.3 0.009
Body mass index, kg/m2 24.4 ± 5.3 24.0 ± 4.4 22.9 ± 3.2 0.23
History of smoking 16.4 19.0 23.7 0.59
Aspirin intolerance 11.5 18.3 27.1 0.04
Atopic dermatitis 16.4 3.3 24.1 0.36
Allergic rhinitis 57.4 68.3 76.3 0.03
Chronic rhinosinusitis with nasal polyps 31.7 42.4 48.3 0.09
Olfactory dysfunction 16.4 28.3 46.6 0.001
Poor adherence to the treatment 3.5 10.0 8.6 0.23
Daily dose of inhaled corticosteroids, mgz 611 ± 348 638 ± 303 676 ± 356 0.31
Patients treated with daily oral corticosteroids 27.7 26.1 32.3 0.70
Patients treated with omalizumab 11.1 7.8 11.1 1.00
Laboratory measurements
Eosinophils/ml of blood 319 ± 490 469 ± 629 584 ± 540 <0.001
Total serum IgE, IU/ml, median (interquartile range) 250 (73e654) 325 (98e636) 313 (134e643) 0.34
Atopic type 62.9 59.4 52.4 0.28
Interleukins (IL)
Serum IL-4, pg/dl 11.7 ± 7.6 14.3 ± 8.9 15.3 ± 9.1 0.06
Serum IL-5, pg/dl 34.0 ± 18.9 40.1 ± 20.6 41.0 ± 22.8 0.22
Serum IL-13, pg/dl 22.0 ± 22.0 20.2 ± 7.5 30.4 ± 44.1 0.06
Pulmonary function (n ¼ 173)
VC, % predicted 92.8 ± 16.1 96.2 ± 20.2 90.5 ± 16.5 0.32
FEV1, % predicted 83.3 ± 22.7 87.5 ± 22.9 76.1 ± 20.0 0.07
FEV1/FVC, % 67.2 ± 14.2 67.5 ± 11.7 61.4 ± 13.4 0.02
Fractional exhaled nitric oxide, ppb (n ¼ 80) 45.9 ± 61.7 40.6 ± 35.9 49.3 ± 46.9 0.50
Computed tomography (n ¼ 55)
Wall area, % 59.1 ± 9.7 57.7 ± 7.0 56.9 ± 6.8 0.51
Asthma severity and quality of life scores
Asthma Control Test 19.7 ± 4.7 19.3 ± 5.3 20.2 ± 4.6 0.53
Asthma Quality of Life Questionnaire 4.9 ± 1.2 4.8 ± 1.3 4.8 ± 1.3 0.88
Values are proportions of patients in each study groups or means ± SD if not otherwise speciﬁed.
IgE, immunoglobulin E; VC, vital capacity; FEV1, Forced expiratory volume in 1 s; FVC, forced vital capacity.
y Low versus High periostin group.
z Dose of inhaled corticosteroids are shown as ﬂuticasone propionate equivalent.
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Since asthma is a heterogeneous disease, its treatment, espe-
cially when severe, should be based on the speciﬁc molecular
mechanism identiﬁed in each individual patient. The serum peri-
ostin concentration was expected to be a reliable surrogate marker
of IL-13 activity in vivo and of persistent eosinophilic inﬂammation
in the airways. The present study adds further evidence that serum
periostin is clinically useful, by showing that its concentration is
correlated with a speciﬁc phenotype of asthma, instead of with its
severity.
Periostin is localized with other matricellular proteins in the
subepithelial layer of the airways. Its elevated expression in bron-
chial epithelial cells is related to subepithelial ﬁbrosis of the air-
ways.6 Furthermore, the serum periostin concentrations correlate
with an annual decline in FEV1, independently of the severity of
asthma or smoking history, in asthmatics treated with inhaled
corticosteroids.10 Therefore, periostin seems to contrast with other
biomarkers of asthma, such as YKL-40 and C-reactive protein,
which reﬂect airway inﬂammation, but not a speciﬁc phenotype
such as a rapid deterioration of pulmonary function.19 Our obser-
vation that patients with high serum periostin concentrations had
low FEV1 and FEV1/FVC in spite of shorter duration of asthmaconﬁrms that periostin is a biomarker of rapid decline in pulmo-
nary function. However, we could not show a relationship between
serum periostin concentrations and airway remodelling assessed
by the airway wall thickness on computed tomography
morphometry. That relationship will require further studies.
The “high-periostin” phenotype identiﬁed in our study, i.e. late-
onset asthma with eosinophilia and concomitant nasal disorders,
corresponds to the phenotypes/endotypes proposed by other re-
searchers. A cluster analysis of severe asthma suggested the pres-
ence of an inﬂammation-predominant phenotype, characterized by
a later onset of the disease with active eosinophilic inﬂammation.20
Another study also described a population of patients with severe,
adult-onset asthma, who were more likely to be non-atopic, asso-
ciated with increased concentrations of exhaled nitric oxide and
sputum eosinophils, and in whom nasal symptoms and polyposis
were more prevalent.21 This late-onset, hypereosinophilic asthma
is also considered a speciﬁc endotype.22
We found that high concentrations of serum periostin were
correlated with other nasal disorders, such as allergic and non-
allergic rhinosinusitis. Among the nasal disease manifestations,
the combination of chronic rhinosinusitis with nasal polyps and
olfactory dysfunction was most prominently correlated with high
concentrations of serum periostin. The combination of nasal polyps
Fig. 2. Relationships between serum periostin concentrations and concomitant nasal
disorders. The serum periostin concentrations in patients with versus without
concomitant nasal disorders are compared. NP þ O, chronic rhinosinusitis with nasal
polyps þ olfactory dysfunction; NP, chronic rhinosinusitis with nasal polyps without
olfactory function; O, olfactory dysfunction without chronic rhinosinusitis with nasal
polyps; AR, allergic rhinitis alone. Bars indicate median values. KruskaleWallis test and
ManneWhitney test were used to compare the groups. P ¼ 0.003; KruskaleWallis,
P ¼ 0.001; ManneWhitney (NP þ O vs. none).
Table 3





Serum periostin concentrationy 0.16 0.03
Multiple variable
Unadjusted
Serum periostin concentrationy 0.15 0.05
Disease duration 0.31 <0.001
History of smoking 0.16 0.04
Adjusted for age and sex
Serum periostin concentrationy 0.06 0.42
Disease duration 0.27 <0.001
History of smoking 0.03 0.70
FEV1, Forced expiratory volume in 1 s; FVC, forced vital capacity.
y Log-transformed.
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eosinophilic rhinosinusitis, often complicated by peripheral blood
eosinophilia and aspirin-intolerant asthma.23 Therefore, a high
proportion of our patients presenting with both chronic rhinosi-
nusitis with nasal polyps and olfactory dysfunction might have
suffered from chronic eosinophilic rhinosinusitis, though this was
not conﬁrmed by pathologic studies. PeriostinmRNA is increasingly
expressed in the nasal mucosa of patients presenting with chronic
eosinophilic rhinosinusitis with nasal polyps.24,25 Therefore, the
concentrations of serum periostin may reﬂect an increased pro-
duction of this molecule in both the upper and the lower airways.
It has been considered that early-onset atopic asthma is a TH2-
related disease,1 however, our study showed that the high serum
periostin concentrations were not correlated with serum concen-
trations of IgE or atopic status, and rather associated with late-
onset asthma. It has been reported that the expression of peri-
ostin is decreased by corticosteroids,6,7 therefore, the periostin
concentrations in early-onset atopic asthma might have been
decreased by corticosteroid. The reason why the concentrations of
periostin remained elevated despite corticosteroids in adult-onseteosinophilic asthma has not been clear yet. In in vitro experi-
ments, corticosteroids completely inhibited the IL-4/13-induced
periostin production in ﬁbroblasts, and enhanced it in microvas-
cular endothelial cells, however, the TGF-b-induced production of
periostin in ﬁbroblasts is resistant to corticosteroids,26 suggesting
that the site or microenvironment of periostin synthesis might be
different in early-versus late-onset asthma. Serum periostin levels,
therefore, can be a useful biomarker to identify speciﬁc phenotypes
of severe asthma independently of atopic status.
Study limitations
The diagnoses of concomitant disorders, such as aspirin-
intolerant asthma, atopic dermatitis, allergic rhinitis and chronic
rhinosinusitis with nasal polyps were based on the patients' an-
swers to the questionnaire, not on objective measurements from
challenge tests, or radiographic and pathological examinations.
Therefore, patients with asymptomatic concomitant diseases may
have been missed in the analysis. Second, since this study was
based on a cross-sectional analysis, we could not determine
whether the concentrations of periostin in serum were stable
through the course of the disease, or varied according to its control
or therapeutic interventions. Third, we have no data whether
serum periostin levels can be inﬂuenced by age or sex, therefore,
the difference in serum periostin levels between healthy subjects
and asthmatic patients may have been compromised by the dif-
ference in age and gender distribution.
In conclusion, periostin is a biomarker that reliably identiﬁes a
TH2-related asthma, late-onset, eosinophilic, and often compli-
cated with declining pulmonary function and nasal diseases,
chronic eosinophilic rhinosinusitis in particular.
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